tbuckley/cabot-search huggingface dataset:
Abstract 16890: WW45 is Required for Mst1-Dependent Inactivation of YAP and Promotion of Myocardial Damage During Ischemia-Reperfusion
Authors: Sebastiano Sciarretta, Peiyong Zhai, Junichi Sadoshima
Journal: Circulation (2011)

The mammalian homolog of Drosophila Hippo, Mst1, is a kinase which negatively regulates cardiomyocyte (CM) growth and survival. Mst1 promotes CM apoptosis in response to oxidative stress and mediates myocardial ischemia-reperfusion (I/R) injury. In Drosophila , the adaptor protein Salvador is required for activation and function of Hippo. We investigated the role of the mammalian homolog of Salvador, WW45, in the regulation of Mst1 activity in the heart. To address this issue, we studied the cardiac phenotype of cardiac-specific WW45 knock-out (W-cKO) mice. At baseline, W-cKO mice were characterized by a mild increase in LV weight/body weight compared to controls (3.44 ± 0.13 vs. 2.92 ± 0.10 mg/g; p&lt;0.05) and normal cardiac function, suggesting that endogenous WW45 negatively regulates baseline growth of the heart. After I/R (30 minutes/24 hours), W-cKO mice exhibited a significantly smaller infarct size/area at risk than controls (20.4 ± 6.0 vs. 38.2 ± 4.5%; p&lt;0.05). Interestingly, Mst1 activation, as evaluated by its phosphorylation status (Thr183), was significantly reduced in W-cKO mice both at baseline (0.5 ± 0.01 fold, p&lt;0.05) and during reperfusion (0.37 ± 0.04 fold, p&lt;0.05), indicating that WW45 is required for Mst1 activation. Co-immunoprecipitation analysis showed that WW45 physically interacts with Mst1 in CMs. We further evaluated whether downregulation of WW45 affects the phosphorylation status (Ser127) and the accumulation of Yes-associated protein (YAP), a transcription factor co-factor which promotes cellular growth and survival. YAP is phosphorylated by the Hippo pathway, and, upon its phosphorylation, YAP is exported from the nucleus and degraded. The level of YAP was increased in the hearts of W-cKO mice at baseline (2.6 ± 0.03 fold, p&lt;0.05) and during reperfusion (4.2± 0.16 fold, p&lt;0.05), and its relative phosphorylation status was decreased (-64% and -75%, p&lt;0.05), indicating that WW45 positively regulates phosphorylation of YAP. There was a significant increase in nuclear localization of YAP during I/R in W-cKO CMs compared to in control CMs (2.2 ± 0.26 fold, p&lt;0.05). In conclusion, our data suggest that endogenous WW45 is required for Mst1-dependent inactivation of YAP and promotion of myocardial damage during I/R.
Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting
Authors: E. Fountzilas, G.-A. Koliou, V. Rapti, A. Nikolakopoulos, A. Christopoulou, E. Moirogiorgou, I. Binas, G. Aravantinos, L. Kostadima, A. Nikolaidi, S. Karteri, F. Zagouri, Z. Saridaki, A. Molfeta, P. Oikonomopoulou, E. Res, D. Tryfonopoulos, G. Koumakis, G. Fountzilas, E. Razis
Journal: Annals of Oncology (2019)
Tobacco use in lung cancer (LC) patients (p) in Spain
Authors: E. Carcereny Costa, M. Guirado, C.J. Camps Herrero, J. Bosch Barrera, M.-R. García-Campelo, A.L. Ortega Granados, J.L. Gonzalez-Larriba, N. De Dios Alvare, M. Domine Gomez, B. Massuti Sureda, M.A. Sala, R. Bernabé, J.M. Oramas Rodriguez, E. del Barco Morillo, A. Padilla, D. Aguiar Bujanda, S. Cerezo Gonzalez, R. Lopez Castro, D. Rodriguez Abreu, M. Provencio
Journal: Annals of Oncology (2019)
Is Dengvaxia a useful vaccine for dengue endemic areas?
Authors: Duane J Gubler, Scott B Halstead
Journal: BMJ (2019)

An effective dengue vaccine that provides balanced protection is still elusive, and <b>Duane J Gubler</b> argues that some partially effective vaccines offer overall benefit—but <b>Scott B Halstead</b> says that this would need a completely new serotesting regimen to avert serious harm
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Authors: C. Le Tourneau, J.-P. Delord, P. Cassier, D. Loirat, A. Tavernaro, B. Bastien, K. Bendjama
Journal: Annals of Oncology (2019)
IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)
Authors: M. Reck, S.V. Liu, A.S. Mansfield, T.S.K. Mok, A. Scherpereel, N. Reinmuth, M.C. Garassino, JCastro De Carpeno, R. Califano, M. Nishio, F. Orlandi, J A Alatorre Alexander, T.A. Leal, Y. Cheng, J.-S. Lee, S. Lam, M. McCleland, Y. Deng, S. Phan, L. Horn
Journal: Annals of Oncology (2019)
Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in oesophageal adenocarcinoma
Authors: E. Ococks, A. Frankell, N. Masque-Soler, A. Northrop, G. Devonshire, C. Hughes, N. Grehan, E. Smyth, A. Blasko, R. Fitzgerald
Journal: Annals of Oncology (2019)
The Role of Metabolic Plasticity in Blood and Brain Stem Cell Pathophysiology
Authors: Catherine J. Landis, Jonathan McConathy, Victor Darley-Usmar, Anita B. Hjelmeland
Journal: Cancer Research (2019)

Abstract Our understanding of intratumoral heterogeneity in cancer continues to evolve, with current models incorporating single-cell signatures to explore cell–cell interactions and differentiation state. The transition between stem and differentiation states in nonneoplastic cells requires metabolic plasticity, and this plasticity is increasingly recognized to play a central role in cancer biology. The insights from hematopoietic and neural stem cell differentiation pathways were used to identify cancer stem cells in leukemia and gliomas. Similarly, defining metabolic heterogeneity and fuel-switching signals in nonneoplastic stem cells may also give important insights into the corresponding molecular mechanisms controlling metabolic plasticity in cancer. These advances are important, because metabolic adaptation to anticancer therapeutics is rooted in this inherent metabolic plasticity and is a therapeutic challenge to be overcome.
HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome
Authors: Guang Yang, Jinyan Feng, Yunxia Liu, Man Zhao, Ying Yuan, Hongfeng Yuan, Haolin Yun, Mingming Sun, Yanan Bu, Lei Liu, Zixian Liu, Jun-qi Niu, Ming Yin, Xijun Song, Zhenchuan Miao, Zhongqing Lin, Xiaodong Zhang
Journal: Theranostics (2019)

Rationale: Hepatitis B virus (HBV) is a leading cause of liver diseases.HBV covalently closed circular DNA (cccDNA) is a critical obstacle of complete elimination by anti-HBV therapy.HBV cccDNA accumulates in nucleus as a chromatin-like cccDNA minichromosome assembled by histones and non-histones.However, the underlying mechanism of modulation of cccDNA minichromosome in hepatocytes is poorly understood.Methods: A human liver-chimeric mouse model was established.The cccDNA-ChIP, Southern blot analysis, confocal assays, RIP assays and RNA pull-down assays, et al. were performed to assess the mechanism of assembly and epigenetic regulation of cccDNA minichromosome in human liver-chimeric mouse model, human primary hepatocytes (PHH), dHepaRG, HepG2-NTCP cell lines and clinical liver tissues.Results: Importantly, the expression levels of HAT1, CAF-1 and lncRNA HULC were significantly elevated in the liver from HBV-infected human liver-chimeric mice.Strikingly, the depletion of HAT1 reduced HBV replication and cccDNA accumulation, and impaired the assembly of histone H3/H4 and the deposition of HBx and p300 onto cccDNA to form cccDNA minichromosome in the cells.Mechanically, chromatin assembly factor-1 (CAF-1) was involved in the events.Interestingly, HAT1 modified the acetylation of histone H3K27/H4K5/H4K12 on cccDNA minichromosome.Moreover, lncRNA HULC-scaffold HAT1/HULC/HBc complex was responsible for the modification on cccDNA minichromosome.Additionally, HBV activated HAT1 through HBx-co-activated transcriptional factor Sp1 in a positive feedback manner.Conclusion: HAT1 signaling contributes to assembly and epigenetic regulation of HBV cccDNA minichromosome.
Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)
Authors: R Lozano Mejorada, D. Lorente, E. Castro, D. Bianchini, P. Nombela, S.K. Sandhu, N Romero Laorden, Y. Cendón, A. Sharp, E Almagro Casado, M.I. Pacheco, P. Rescigno, C. LLácer, M. Saez, L. Rivera, F. Vitrone, C. Moreno, J. Mateo, J.S. de Bono, D Olmos Hidalgo
Journal: Annals of Oncology (2019)
Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
Authors: M. De Laurentiis, M. Mazza, M. Mansutti, R. Masetti, Z. Ballatore, R. Torrisi, A. Michelotti, A. Zambelli, A. Ferro, D. Generali, P. Vici, L. Coltelli, A. Fabi, P. Marchetti, A. Ballestrero, S. Spazzapan, A. Frassoldati, G. Sarobba, D. Grasso, C. Zamagni
Journal: Annals of Oncology (2019)
Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) By Age Group over 35 Years: A Single Institution Experience
Authors: Koji Sasaki, Elias J. Jabbour, Susan M. O'Brien, Deborah A Thomas, Farhad Ravandi, Guillermo Garcia-Manero, Jorge E. Cortes, Nicholas J. Short, Srdan Verstovsek, Musa Yilmaz, William G. Wierda, Gautam Borthakur, Tapan M. Kadia, Marina Konopleva, Maria R. Khouri, Alessandra Ferrajoli, Naval G. Daver, Naveen Pemmaraju, Courtney D DiNardo, Nitin Jain, Christopher B. Benton, Koichi Takahashi, Kiran Naqvi, Prithviraj Bose, Steven M. Kornblau, Michael Andreeff, Michael J. Keating, Emil J. Freireich, Hagop M. Kantarjian
Journal: Blood (2016)
Imatinib Resistance and/or Intolerance in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.
Authors: Mauricette Michallet, Enrica Morra, Juan Steegmann, David Marin Costa, Gert Ossenkoppele, Gregor Verhoef, Thomas Kühr, Mats Björeman, Muriel Sterckx, Claire Cropet, Isidro Villanueva, Laurence Van Bree, Karin Cerri
Journal: Blood (2007)
Mortality Assessment of Paclitaxel-Coated Balloons
Authors: William A. Gray, Michael R. Jaff, Sahil A. Parikh, Gary M. Ansel, Marianne Brodmann, Prakash Krishnan, Mahmood K. Razavi, Frank Vermassen, Thomas Zeller, Roseann White, Kenneth Ouriel, Mark A. Adelman, Sean P. Lyden
Journal: Circulation (2019)

Background: A recent summary-level meta-analysis comprising randomized, controlled trials (RCTs) of femoropopliteal paclitaxel-coated balloon and stent intervention identified excess late mortality in the paclitaxel-treated patients. Methods: We evaluated the safety of the Stellarex drug-coated balloon (DCB) for femoropopliteal artery disease with an independently performed meta-analysis of patient-level data from all patients in the Stellarex femoropopliteal clinical program. To compare mortality after DCB or uncoated percutaneous transluminal angioplasty (PTA), we aggregated data from 2 RCTs comprising 419 patients treated with DCB and 170 patients treated with PTA. In an additional analysis, data were aggregated from 6 poolable Stellarex DCB studies (2 RCTs, 3 single-arm studies, and 1 registry). All serious adverse events including deaths were adjudicated by a blinded, third-party, independent Clinical Events Committee. Kaplan–Meier estimates in the RCTs were compared with restricted mean survival time. Predictors of death were assessed with hazard ratios (HRs) and Cox proportional hazards modeling. Results: Baseline characteristics were similar in the patients treated with DCB and PTA in the pooled RCT analysis, with the exception that the DCB cohort was younger (67.4±9.7 versus 69.4±9.4 years, P =0.02), smoked more frequently (86.6% versus 78.8%, P =0.02), and were less often treated for recurrent lesions (8.8% versus 14.7%, P =0.04). In the RCTs, patients treated with DCB had all-cause mortality rates that were not different from those of patients treated with PTA (Kaplan–Meier estimates 1.8±0.7% versus 1.3±0.9%, 6.5±1.2% versus 5.9±1.9%, and 9.3±1.5% versus 9.9±2.4% at 1, 2, and 3 years, respectively, P =0.86). All-cause mortality rates were similar in a 1906-patient pooled nonrandomized DCB data set (Kaplan–Meier estimates of 2.1%, 4.9%, and 7.0% at 1, 2, and 3 years, respectively). Clinical Events Committee–adjudicated causes of death were balanced between the DCB and PTA cohorts. Multivariable Cox modeling identified age (HR, 1.06; 95% CI, 1.04–1.08; P &lt;0.001), diabetes mellitus (HR, 1.42; 95% CI, 1.01–2.00; P =0.04), congestive heart failure (HR, 1.88; 95% CI, 1.12–3.16; P =0.02), and renal insufficiency (HR, 2.00; 95% CI, 1.33–3.01; P &lt;0.001) as predictors of mortality. Paclitaxel exposure was unrelated to mortality (HR, 1.04; 95% CI, 0.98–1.10; P =0.23). Conclusions: The mortality rates for patients treated with the DCB and uncoated PTA were indistinguishable over 3-year follow-up. Additional patient-level, adequately powered meta-analyses with larger RCT data sets will be needed to confirm the generalizability of these findings. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifiers: NCT02110524, NCT01858363, NCT01858428, NCT03421561, NCT01912937, NCT01927068, and NCT02769273.
Avoiding Harm From Hyperbilirubinemia Screening—Reply
Authors: Scott D. Grosse, Lisa A. Prosser, Jeffrey R. Botkin
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
First in human phase I/IIa study of PEN-866, a heat shock protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumours: Phase I results
Authors: J.C. Bendell, G. Falchook, S. Sen, M.L. Johnson, G. Jerkovic, N. Sarapa, R. Vilimas, K. Kriksciukaite, L. Mei, R. Wooster, J. Bloss, A. Thomas
Journal: Annals of Oncology (2019)
Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy
Authors: F. Marmé, C. Solbach, L. Michel, P.A. Fasching, A. Schneeweiss, J.-U. Blohmer, M. Rezai, J. Huober, C. Jackisch, V. Nekljudova, T. Link, K. Rhiem, C. Denkert, C. Hanusch, H. Tesch, B. Lederer, S. Loibl, M. Untch
Journal: Annals of Oncology (2019)
Upfront radical surgery with total mesorectal excision (TME) versus preoperative chemoradiotherapy followed by TME in clinical stage II/III patients with rectal cancer: A propensity score analysis
Authors: A. Ham, H.S. Kim, J.S. Chang, S.J. Shin, S.-H. beom, W.S. Koom, T. Kim, H. Hur, B.S. Min, K.Y. Lee, N.K. Kim, J.S. Lim, J.-B. Ahn
Journal: Annals of Oncology (2019)
Circulating tumour DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Authors: R.S. Heist, M. Motwani, L. Naumovski, J. Wu, B.A. Bach, X. Lu, K. Kelly
Journal: Annals of Oncology (2019)
Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumours
Authors: A.A. Davis, W. Iams, D. Chan, M.S. Oh, R.W. Lentz, R. Srivas, N. Lambert, A. Robertson, N. Peterman, A. Shah, T. Wilson, J. Close, P. George, H. Wood, B. Wong, A. Tezcan, J.C. Spinosa, H. Tezcan, Y.K. Chae
Journal: Annals of Oncology (2019)
Docetaxel for hormone-naïve prostate cancer (PCa): Results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial
Authors: N.D. James, F.C. Ingleby, N.W. Clarke, C. Amos, G. Attard, W. Cross, D. Dearnaley, D. Gilbert, R. Jones, R. Langley, M.D. Mason, D. Matheson, C. Parker, A. Ritchie, H.L. Rush, M. Russell, R. Pereira Mestre, M.K.B. Parmar, M.R. Sydes
Journal: Annals of Oncology (2019)
Loss of Xanthine Oxidoreductase Potentiates Propagation of Hepatocellular Carcinoma Stem Cells
Authors: Qikai Sun, Zechuan Zhang, Yijun Lu, Qiaoyu Liu, Xiaoliang Xu, Jianbo Xu, Yang Liu, Hailong Yu, Decai Yu, Beicheng Sun
Journal: Hepatology (2019)

Background and Aims Liver cancer stem cells (CSCs) exist in the tumor environment and are critically involved in the initiation and progression of hepatocellular carcinoma (HCC). However, the underlying molecular mechanisms of self‐renewal and maintenance of liver CSCs remain poorly understood. Approach and Results We identified that xanthine oxidoreductase (XOR), which was expressed at low levels in human HCC samples and liver CSCs, restrained HCC formation and chemoresistance by attenuating liver CSC propagation. Mechanistically, XOR physically interacts with ubiquitin‐specific peptidase 15 (USP15), thereby promoting deubiquitination of Kelch‐like ECH associated protein 1 (KEAP1) to stabilize its expression, which leads to degradation of Nrf2 (nuclear factor erythroid 2–related factor 2) through ubiquitination and subsequently reactive oxygen species accumulation in liver CSCs. Finally, our data reveal that XOR promotes USP15‐mediated Nrf2‐KEAP1 signaling to block liver CSCs and tumor propagation. Conclusion We identified that XOR may represent a potential therapeutic target for clinical intervention in HCC driven by liver CSCs.
Effect of leptomycin B (LMB) and verapamil (VER) on total cell uptake and nuclear transport of [C14]-doxorubicin (C14-DOX), [H3]-etoposide (H3-ETOP) and [C14]-5-fluorouracil (C14-5-FU) in drug-sensitive (W-SKNSH) and drug-resistant (DOX6-SKNSH; ETOP5-SKNSH) human neuroblastoma cells
Authors: Baojun Chang, Sandra H. Clark, Bernard L. Mirkin
Journal: Cancer Research (2005)

535  The onset of resistance to some cancer chemotherapeutic agents has been correlated with their increased export and decreased cell uptake, which is generally attributed to upregulation of P-glycoprotein (P-gp) expression. Alterations in nuclear transport and sequestration of cytotoxic drugs in subcellular organelles may also play an important role in this adaptive process. The effect of LMB and VER on total cell and nuclear uptake of C14-DOX, H3-ETOP and C14-5-FU in W-SKNSH, DOX6-SKNSH and ETOP5-SKNSH cells has been investigated. Cells were incubated with radiolabeled drugs for differing time periods and uptake determined in the presence or absence of VER (10 μM) and LMB (0.1, 1, 10 ng/ml). Total cell uptake of C14-DOX in W-, DOX6- and ETOP5-SKNSH cells was 168, 10, and 18 (ng/mg prot), respectively. Pre-incubation of cells for 24 hrs with VER did not affect W-SKNSH cells (172 ng/mg prot) but increased the uptake in both resistant cell lines to 68, and 103 (ng/mg prot), respectively. The nuclear uptake of C14-DOX in these cells (same order) was 485, 20, and 44 (ng/mg prot) without VER, and 456, 203, and 307 (ng/mg prot) with VER. While inhibition of P-gp by VER did not affect W-SKNSH cells, the total uptake of C14-DOX in DOX6- and ETOP5-SKNSH cells was elevated 6 to 7-fold and nuclear uptake, 7 to 10-fold above controls. In contrast, total cell uptake of H3-ETOP in W-, DOX6- and ETOP5-SKNSH cells was 7, 1, and 1.1 ng/mg prot, compared to 7.6, 2.6, and 3.8 ng/mg prot when pre-incubated with VER. Nuclear uptake of H3-ETOP was 0.7, 0.41, and 0.35 ng/mg prot in the absence of VER, and essentially unchanged, 0.67, 0.44, and 0.48 ng/mg prot, after VER pre-incubation. Total cell and nuclear uptake of H3-ETOP was significantly lower than C14-DOX in all cell lines. Neither total cell or nuclear uptake of 5-FU differed significantly between wild and drug-resistant cells. Pre-incubation with the nuclear export inhibitor LMB (10 ng/ml) for 4 hrs increased C14-DOX total cell and nuclear uptake in W-SKNSH cells 1.4 and 1.1-fold, compared to 3.3 and 3.95-fold in DOX-SKNSH cells. The cytotoxic potency of DOX in DOX6-SKNSH cells was increased 100-fold by VER, compared to ETOP, which was enhanced 10-fold (p
Health-related quality of life (HRQoL) and updated follow-up from KEYNOTE-057: Phase II study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG)
Authors: R. de Wit, G.S. Kulkarni, E. Uchio, J.L. Boormans, M. Roumiguié, L.E.M. Krieger, E.A. Singer, D.F. Bajorin, A.M. Kamat, P. Grivas, H.K. Seo, H. Nishiyama, B.R. Konety, T. Saretsky, H. Li, K. Nam, E. Sbar, A.V. Balar
Journal: Annals of Oncology (2019)
Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in
Authors: M. Davidson, S. Mansukhani, N. Starling, I. Chau, D. Watkins, D. Cunningham, S. Rao, R. Lazaro-Alcausi, B. Griffiths, L. Barber, D. Morganstein, M.D. Forster, S. Davies, R. Begum, A. Gillbanks, E. Kalaitzaki, A. Wotherspoon, K. Von Loga, A. Chaudry, M. Gerlinger
Journal: Annals of Oncology (2019)
Dabigatran versus warfarin in patients with atrial fibrillation: Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators
Authors: Kenneth Egstrup
Journal: New England Journal of Medicine (2009)
Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Authors: C. Robert, D. Schadendorf, R. Dummer, K.T. Flaherty, H.A. Tawbi, A.M. Menzies, A. D’Amelio, E. de Jong, E. Gasal, G.V. Long
Journal: Annals of Oncology (2019)
No need to cut red meat, say new guidelines
Authors: Owen Dyer
Journal: BMJ (2019)

Adults should continue their current consumption of red meat and processed meat, say the recommendations of an international panel published in the Annals of Internal Medicine .1

The guideline—a striking departure from most existing recommendations—is based on the findings of four other papers published in the same issue, which review existing studies in the field to assess the risk of various cardiometabolic and cancer outcomes, incidence, and mortality.2345

A fifth paper provides a meta-analysis of studies examining people’s attitudes to meat and their resistance to dietary change.6 It concludes that “omnivores are attached to meat and are unwilling to change this behaviour when faced with potentially undesirable health effects.”

The findings are at odds with most other analyses, even those relying on the same data, largely …
Choosing the right strategy based on individualized treatment effect predictions: Combination versus sequential chemotherapy in patients with metastatic colorectal cancer
Authors: M. Koopman, J.J. Kwakman, R.C.M. van Kruijsdijk, S.G. Elias, M.T. Seymour, A.M. Meade, F. Visseren, C.J.A. Punt
Journal: Annals of Oncology (2019)